Zevra Therapeutics (ZVRA) Other Non-Current Liabilities (2016 - 2026)

Zevra Therapeutics has reported Other Non-Current Liabilities for 11 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 57.5% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (down 57.5% YoY), and the FY2025 full-year result was $1.7 million, down 63.0% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $6.9 million, up from $1.7 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $17.5 million in Q3 2025, with the low at $25000.0 in Q4 2022.
• Historically, Other Non-Current Liabilities has averaged $5.5 million across 5 years, with a median of $4.6 million in 2024.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities jumped 5303.16% — and 2025, when it sank 63.0%.
• Zevra Therapeutics' Other Non-Current Liabilities stood at $25000.0 in 2022, then surged by 532.0% to $158000.0 in 2023, then jumped by 2830.38% to $4.6 million in 2024, then slumped by 63.0% to $1.7 million in 2025, then soared by 301.11% to $6.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $6.9 million (Q1 2026), $1.7 million (Q4 2025), and $17.5 million (Q3 2025), per Business Quant data.